Pregnancy and live birth after follicle-stimulating hormone treatment for an infertile couple including a male affected by Sertoli cell-only syndrome

Gianni Paulis, Luca Paulis, Gennaro Romano, Carmen Concas, Marika Di Sarno, Renata Pagano, Antonio Di Filippo, Maria Luisa Di Petrillo

1Andrology Center, Regina Apostolorum Hospital, Rome, Italy; 2Department of Uro-Andrology, Castelfidardo Medical Team, Peyronie’s Disease Care Center, Rome, Italy; 3Section of Pharmacology and Research, Department of Uro-Andrology, Castelfidardo Medical Team, Peyronie’s Disease Care Center, Rome, Italy; 4Department of Urologic Oncology, Italian League Against Cancer, Avellino, Italy; 5Department of Reproductive Medicine and Biology, Caran Center, Caserta, Italy

Abstract: In males with nonobstructive azoospermia, one of the main histopathologic patterns of the testis is Sertoli cell-only syndrome (SCOS), in which no germ cells are present and only Sertoli cells are contained in the seminiferous tubules. There is not any formal treatment for this pathological condition. However, several studies reported the possibility to perform testicular sperm extraction in patients with SCOS, although, according to some authors, sperm retrieval is possible only in the presence of focal spermatogenesis. We report the case of an infertile couple in whom the 30-year-old male was azoospermic. After the diagnosis, the patient underwent multiple bilateral testicular biopsies, which showed a histological pattern corresponding to SCOS. We administered a cycle of hormone stimulation followed by medically assisted reproduction procedures to the male patient. Therefore, the male patient was treated with follicle-stimulating hormone gonadotropin for a total of 7 months (150 IU recombinant human follicle stimulating hormone three times per week). After carrying out a new multiple testicular sperm extraction, several spermatozoa were microscopically observed, and it was then possible to perform an intracytoplasmic sperm injection with subsequent embryo transfer of the blastocyst into the wife’s uterus, and so pregnancy was established and developed. Subsequently, the pregnancy resulted in the live birth of a girl.

Keywords: azoospermia, Sertoli cell-only syndrome, FSH, ICSI, TESE sperm retrieval, live birth pregnancy

Introduction
Infertility is a problem that globally affects 15% of couples who have regular unprotected sexual intercourse.1,2 In about 50% of cases of infertility, the exclusive cause is attributed to the female, in 20%–30% of cases to the male, while in the remaining 20%–30% of cases, infertility is the result of a combination of male and female causes.1

Azoospermia has been identified in 15% of infertile males and can be classified as obstructive azoospermia (OA) and nonobstructive azoospermia (NOA).3 OA accounts for 40% of azoospermia cases: in these cases, the endocrine and exocrine functions of the testes are preserved and spermatogenesis in the testis is normal. OA is caused by an obstruction of the male duct system and may occur in any region between the rete testis and the ejaculatory ducts. NOA affects ~1% of the general population, 10% of infertile men, and 60% of azoospermic men.3–5 NOA results from either primary testicular failure, secondary testicular failure, or incomplete or ambiguous testicular failure. In males with NOA, the main histopathological patterns of the testis are the following: hypospermatogenesis, maturation arrest, Sertoli cell-only syndrome (SCOS), incomplete Sertoli cell-only syndrome ([SCOS type II] in which only a few tubules

Correspondence: Gianni Paulis
Castelfidardo Medical Team, Peyronie’s Disease Care Center, Via Castelfidardo, 34, Rome 00185, Italy
Email paulisg@libero.it
contain germ cells), and complete and homogeneous hyalinization of seminiferous tubules which appear completely acellular.5–7

In the SCOS pattern, no germ cells are present and only Sertoli cells are contained in the seminiferous tubules, but the tubular architecture is not affected by fibrosis. Prevalence of SCOS in azoospermic patients varies between 26.3% and 57.8% of cases.8–12 Many SCOS patients have a normal karyotype and normal secondary male sexual characteristics; other patients have reduced testicular volume and high follicle-stimulating hormone (FSH) levels. Whereas for many of these patients the cause is unknown, for many others, the following associated conditions have been identified: Klinefelter’s syndrome (47,XXY) or mosaic Klinefelter’s syndrome (46,XY/47,XXY); microdeletions in the azoospermia factor (AZF) region of the Y chromosome; hypogonadotropic hypogonadism; cryptorchidism; estrogen treatment; chemotherapy; exposure to chemicals and toxins; history of testicular hypoxia; and chronic alcohol consumption.13–20 Consequently, a number of authors describe a primary and secondary form of SCOS, while other authors prefer to consider the presence of associated conditions. There is not any formal treatment for SCOS.21 Several studies, however, have reported the possibility to perform testicular sperm extraction (TESE) in patients with SCOS, although according to some authors, there is a likelihood of success (sperm retrieval) only in the presence of focal spermatogenesis within a histologic pattern corresponding to SCOS and complete absence of germ cells in both testicles (Figure 1).

The patient’s medical history revealed no inflammatory episodes or urogenital tract infections. After the diagnosis of azoospermia, the patient underwent multiple bilateral testicular biopsies, which showed a histologic pattern corresponding to SCOS and complete absence of germ cells in both testicles (Figure 1).

The couple immediately rejected the idea of using sperm donation; therefore, after having obtained a shared consent (including informed consent) from the couple, we administered a cycle of hormone stimulation for the production of gametes, followed by medically assisted procreation (MAP) procedures to the male patient.

The male patient was thus treated with FSH gonadotropin for 3 months at the following dosage: 150 IU recombinant human FSH (rFSH) injected under the skin three times per week.

This article is the result of a successful experience of FSH treatment in an SCOS patient, with the appearance of spermatozoa in the seminiferous tubules after about 3 months.

**Clinical case**

We report the case of an infertile couple in whom the 30-year-old male was azoospermic. The diagnosis of azoospermia was ascertained by at least two semen analyses, following the World Health Organization guidelines.21 The 27-year-old wife, although suffering from polycystic ovary syndrome, did not present any particular problems, and her hormone assays were normal. Physical examination of the man revealed normal secondary male sexual characteristics and the presence of both testes, of normal volume, and with palpable vasa deferentia at the root of the scrotum. His hormone profile, however, was altered: FSH=15 mUI/mL (normal reference range=1.55–9.74 mUI/mL/chemiluminescence) and total testosterone=21.9 mmol/L (normal reference range=4.0–20.0 mUI/mL/chemiluminescence). The luteinizing hormone assay was instead normal: 9.60 mUI/mL (normal reference range=1.5–14.0 mUI/mL/chemiluminescence). Genetic testing was normal with regards to karyotype, genetic mutations of cystic fibrosis transmembrane conductance regulator (CFTR) gene related to congenital bilateral absence of the vas deferens and cystic fibrosis, Y-chromosomal microdeletions, and deletions of the AZF region (AZFa, AZFb, or AZFc).

![Figure 1](https://www.dovepress.com) Microscopic observation (100× magnification) before and after FSH treatment.

**Notes:** (A) Histologic patterns before treatment: Sertoli cell-only syndrome. (B) Appearance of sperm cells after FSH treatment (first cycle). (C) Sperm cells after FSH treatment (second cycle).

**Abbreviation:** FSH, follicle-stimulating hormone.
The female patient (wife) also underwent stimulation, taking 900 UI of rFSH for each cycle: on the 21st day of her cycle, she took a suppressor drug which inhibited FSH and luteinizing hormone production. In the following cycle, she underwent hormone stimulation from the first to the fifth day of her cycle. Follicular growth was monitored with ultrasound and serum estradiol measurement. When follicles were suitable in number and size, human chorionic gonadotropin drug was administered and the oocyte retrieval was performed within 36 hours.

The patients signed an informed consent containing the aspects of the surgical procedure, the modalities of assisted reproduction, and agreement to the publication of this case report and images.

The study was conducted according to the ethical standards of the Declaration of Helsinki.

**Sequence of the MAP procedures**

**MAP (first cycle)**

**Sperm retrieval**

At the end of the 3-month therapy, a multiple TESE was performed. On microscopic observation (100× phase contrast immersion objective), some spermatozoa were observed (Figure 1).

**Intracytoplasmic sperm injection (ICSI)**

Using microscopy, every single spermatozoon was aspirated and injected into the cytoplasm of the six mature oocytes (out of 12 total oocytes) which had previously been retrieved.

**Embryo transfer**

Of the six fertilized oocytes, four developed into zygotes. From them a single blastocyst was obtained, but this time with improved characteristics: grade 4AA = expanded blastocyst with wall thinned – many thickened cells – many cells forming a cohesive layer (according to Gardner’s classification), as shown in Figure 3.28–30

Fifteen days after the embryo transfer, the wife was pregnant.

**Discussion**

This is the first article in the literature describing in detail the case of a patient suffering from SCOS who, after treatment with FSH, produced sperm cells, which were then retrieved...
using TESE. As a result, it was then possible to perform an ICSI with subsequent embryo transfer of the blastocyst into the wife’s uterus and establishment and development of pregnancy, which was uneventful and resulted in the live birth of a girl. In the literature, we found studies in which, in SCOS cases, after recovery of sperm cells through TESE, cases of “ongoing pregnancies” were reported after embryo implantation following ICSI. However, only two of these studies reported that the pregnancies had reached term with the live birth of a baby. The appearance of sperm cells in the seminiferous tubules after treatment with gonadotropin has also been reported in the literature.

In their literature review 10 years ago, Donoso et al. found that microdissection-TESE (or micro-TESE) can lead to higher percentages of sperm retrieval compared to traditional TESE, especially in patients with SCOS, the same study observed that TESE procedures with multiple biopsies make it possible to increase the possibility of sperm retrieval compared to fine needle testicular aspiration, particularly in cases of SCOS. It must be noted that Mulhall et al. did not find, in general, any significant difference in the percentage of sperm retrieval between the two methods, except in cases where mean testicular volumes of 10 mL or less: in those cases, instead, retrieval between the two methods was higher compared to fine needle testicular aspiration, particularly in cases with mean testicular volumes of 10 mL or less: in those cases, instead, microdissection-TESE showed better results.

Currently, there is no consensus on administering gonadotropin to infertile patients with NOA with the aim of increasing the possibility of sperm retrieval; this is partly due to the fact that many patients with SCOS already present baseline FSH serum levels that are higher than normal. Furthermore, various studies have shown that in patients with NOA and SCOS, after TESE, there is a greater likelihood of sperm retrieval where FSH blood levels are higher.

The gonadotropin we used in this case was human rFSH, specifically follitropin alpha, which, from the point of view of biologic activity, is biosimilar to (likewise human recombinant) follitropin beta. From the point of view of biogenetic engineering, in follitropin alpha, two separate vectors, one for each subunit, are used to make up the master cell bank for an FSH-producing cell line, while follitropin beta uses a single vector containing the coding sequences of both subunit genes.

Recombinant follitropin alpha, from the point of view of its therapeutic effect, is interchangeable with urinary gonadotropin (urofollitropin, purified human-derived FSH).

Conclusion

When the histopathologic profile of the azoospermic patient’s testicular biopsy corresponds to SCOS, performance of multiple TESE along with intracytoplasmic sperm injection is certainly indicated as first-line treatment. Multiple TESE is justified, since a focal spermatogenesis site might not coincide with the site of a single testicular sampling. In our case, treatment with FSH gonadotropin was able to lead to the production of sperm cells, which were absent in the first testicular biopsy. The second ICSI cycle and embryo transfer then led to therapeutic success, with the establishment and development of pregnancy and the live birth of a girl.

Acknowledgment

Luca Paulis (Graduate Pharmacist) is the son of Gianni Paulis. Luca collaborates in his father’s studies as in other past articles.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Sharlip ID, Jarow JP, Belker AM, et al. Best practice policies for male infertility. Fertil Steril. 2002;77(5):873–882.
2. Martinez G, Daniels K, Chandra A. Fertility of men and women aged 15–44 years in the United States: National Survey of Family Growth, 2006–2010. Natl Health Stat Rep. 2012;(51):1–28.
3. Wosnitser M, Goldstein M, Hardy MP. Review of Azoospermia. Spermatogenesis. 2014;4:e28218.
4. Willott GM. Frequency of azoospermia. Forensic Sci Int. 1982;20(1–9-10).
5. McLachlan RI, Rajpert-De Meyts E, Hoei-Hansen CE, de Kreter DM, Skakkebaek NE. Histological evaluation of the human testis–approaches to optimizing the clinical value of the assessment: mini review. Hum Reprod. 2007;22(1):2–16.
6. Ostad M, Liotta D, Ye Z, Schlegel PN. Testicular sperm extraction for nonobstructive azoospermia: results of a biopsy approach with optimized tissue dispersion. Urology. 1998;52(4):692–696.
7. Castiglioni M, Colpi EM, Scroppo F, Colpi GM. The Infertile Male-5: Management of Non-Obstructive Azoospermia. In: Bertolotto M, Trombetta C, editors. Scrotal Pathology. Berlin Heidelberg: Springer-Verlag; 2012: 249–261.
8. Shiraishi K, Ohmi C, Shimabukuro T, Matsuyma H. Human chorionic gonadotropin treatment prior to microdissection testicular sperm extraction in non-obstructive azoospermia. Hum Reprod. 2012;27(2):331–339.
9. Parikh UR, Goswami HM, Deliwal, KJ, Shah AM. Testicular biopsy in male infertility (Study of 80 cases). Int J Pathol. 2011;11(2):1.
10. Lekshmi Ammal P, Krishna Das S. Testicular Biopsy in Male Infertility. JMSCR. 2011;5(4):20616–20619.
11. Rashed M, Ragab N, Shalaby A, Ragab W. Patterns of testicular histopathology in men with primary infertility. Int J Pathol. 2007;5(2):1–9.
12. Franco G, Scarselli F, Casciani V, et al. A novel stepwise micro-TESE approach in non obstructive azoospermia. BMC Urol. 2016;16(1):20.
13. Stouffs K, Gheldof A, Tournaye H, et al. Sertoli Cell-Only Syndrome: Behind the Genetic Scenes. Biomed Res Int. 2016;6191307.
14. Paulis G. Chromosomal causes of infertility. In: Cavallini G, Beretta G, editors. Clinical Management of Male Infertility. New York, NY: Springer; 2014:63–77.
15. Foresta C, Ferlin A, Garolla A, et al. High frequency of well-defined Y-chromosome deletions in idiopathic Sertoli cell-only syndrome. Hum Reprod. 1998;13(2):302–307.
16. Bellingham M, McKinnell C, Fowler PA, et al. Foetal and post-natal exposure of sheep to sewage sludge chemicals disrupts sperm production in adulthood in a subset of animals. Int J Androl. 2012;35(3):317–329.

17. Fisher JS, Macpherson S, Marchetti N, Sharpe RM. Human ‘testicular dysgenesis syndrome’: a possible model using in-utero exposure of the rat to dibutyl phthalate. Hum Reprod. 2003;18(7):1383–1394.

18. Gatt Y, Gornish M, Perlow A, et al. Azoozpermia and Sertoli- cell-only syndrome: hypoxia in the sperm production site due to impairment in venous drainage of male reproductive system. Andrologia. 2010;42(5):314–321.

19. Nistal M, Jimenez F, Paniagua R. Sertoli cell types in the Sertoli-cell-only syndrome: relationships between Sertoli cell morphology and etiology. Histopathology. 1990;16(2):173–180.

20. Pajariinen JT, Karhunen PJ. Spermatogenic arrest and ‘Sertoli cell-only’ syndrome—common alcohol-induced disorders of the human testis. Int J Androl. 1994;17(6):292–299.

21. World Health Organization. WHO Laboratory Manual for the Examination and Processing of Human Semen. Fifth edition. World Health Organization; 2010.

22. Berookhim BM, Palermo GD, Zaninovic N, Rosenwaks Z, Schlegel PN. Microdissection testicular sperm extraction in men with Sertoli cell-only testicular histology. Fertil Steril. 2014;102(5):1282–1286.

23. Modarresi T, Hosseini-Mafar H, Dalari Hampa A, et al. Predictive factors of successful microdissection testicular sperm extraction in patients with presumed sertoli cell-only syndrome. Int J Fertil Steril. 2015;9(1):107–112.

24. Ramasamy R, Yagan N, Schlegel PN. Structural and functional changes to the testis after conventional versus microdissection testicular sperm extraction. Urology. 2005;65(6):1190–1194.

25. Talas H, Yaman O, Aydos K. Outcome of repeated micro-surgical testicular sperm extraction in patients with non-obstructive azoospermia. Asian J Androl. 2007;9(5):668–673.

26. Gul U, Turunc T, Haydardedegolu B, Yaycioglu O, Kuzgunbay B, Ozkardes H. Sperm retrieval and live birth rates in presumed Sertoli-cell-only syndrome in testis biopsy: a single centre experience. Androl. 2013;1(1):47–51.

27. Yildirim ME, Koc A, Kaygusuz IC, et al. The association between serum follicle-stimulating hormone levels and the success of microdissection testicular sperm extraction. Hum Reprod Update. 2012;18(5):551–555.

28. Gardner DK, Lane M, Stevens J, Schlenker T, Schoolcraft WB. Blasto-cyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer. Fertil Steril. 2000;73(6):1155–1158.

29. Gardner DK, Surrey E, Minjarez D, Leitz A, Stevens J, Schoolcraft WB. Single blastocyst transfer: a prospective randomized trial. Fertil Steril. 2004;81(3):551–555.

30. Yang Z, Liu J, Collins GS, et al. Selection of single blastocysts for fresh transfer via standard morphology assessment alone and with array CGH for good prognosis IVF patients: results from a randomized pilot study. Mol Cytogenet. 2012;5(1):24.

31. De Croo I, Van der Elst J, Everaert K, Van der Elst J, Heurkens H. The effect of micro-dissection sperm retrieval (m-TESE) is an isolated testicular biopsy necessary in the management of men with non-obstructive azoospermia? BJU Int. 2012;109(3):418–424.

32. Abdel Raheem A, Garaffa G, Rushwan N, et al. Testicular histopathology as a predictor of a positive sperm retrieval in men with non-obstructive azoospermia. BJU Int. 2013;111(3):492–499.

33. Hussein A. Evaluation of diagnostic tests biopsy and the repetition of testicular sperm extraction surgeries in infertility patients. Fertil Steril. 2013;100(1):88–93.

34. Tournaire H, Verheyen G, Nagy P, et al. Are there any predictive factors for successful testicular sperm recovery in azoospermic patients? Hum Reprod. 1997;12(1):80–86.

35. Su LM, Palermo GD, Goldstein M, Veeck LL, Rosenwaks Z, Schlegel PN. Testicular sperm extraction with intracytoplasmic sperm injection for nonobstructive azoospermia: testicular histology can predict success of sperm retrieval. J Urol. 1999;161:112–116.

36. Talas H, Yaman O, Aydos K. Outcome of repeated micro-surgical testicular sperm extraction in patients with non- obstructive azoospermia. Asian J Androl. 2007;9(5):668–673.

37. Kitamura M, Nishimura K, Miura H, et al. Retrieval and cryopreservation of testicular sperm. Hinyokika Kiyo. 2000;46(8):587–590.

38. Ragoza A, Zwalinski M, Brzozka B, Emerich J. Successful treatment of azoospermia in sertoli cell only syndrome: a case report. Ginekol Pol. 1998;69(6):498–501.

39. Donoso P, Tournaire H, Devroey P. Which is the best sperm retrieval technique for non-obstructive azoospermia? A systematic review. Hum Reprod Update. 2007;13(6):539–549.

40. Mulhall JP, Ghaly SW, Alvg N, Ahmed A. The utility of optical loupe magnification for testis sperm extraction in men with nonobstructive azoospermia. J Androl. 2005;26(2):178–181.

41. Atta AM, Abou-Setta AM, Al-Inany HG. Gonadotrophins for idiopathic male factor subfertility. Cochrane Database Syst Rev. 2013(8):CD005971.

42. Ramasamy R, Lin K, Gosden LV, Rosenwaks Z, Palermo GD, Schlegel PN. High serum FSH levels in men with nonobstructive azoospermia does not affect success of microdissection testicular sperm extraction. Fertil Steril. 2009;92(2):590–593.

43. Colpi GM, Colpi EM, Piedferro G, et al. Microsurgical TESE versus conventional TESE for ICSI in non-obstructive azoospermia: a randomized controlled study. Reprod Biomed Online. 2009;18(3):315–319.

44. Bohring C, Schroeder-Printzen I, Weidner W, Krause W. Serum levels of inhibin B and follicle-stimulating hormone may predict successful sperm retrieval in men with azoospermia who are undergoing testicular sperm extraction. Fertil Steril. 2002;78(6):1195–1198.

45. Harlin J, Csemiczky G, Wramsby H, Fried G. Recombinant follicle stimulating hormone in in-vitro fertilization treatment-clinical experience with follitropin alpha and follitropin beta. Hum Reprod. 2000;15(2):239–244.

46. Tulpala M, Aho M, Tuuri T, et al. Comparison of two recombinant follicle-stimulating hormone preparations in in-vitro fertilization: a randomized clinical study. Hum Reprod. 1999;14(11):2709–2715.

47. de Mora F, Fauser BCJM. Biosimilars to recombinant human FSH and menotropins: comparable efficacy and safety to the original biologic. Reprod Biomed Online. 2013;5(1):81–86.

48. Howles CM. Genetic engineering of human FSH (Gonal-F). Hum Reprod Update. 1996;2(2):172–191.

49. Olijve W, de Boer W, Mulders JW, van Wezenbeek PM. Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon). Mol Hum Reprod. 1996;2(2):172–191.

50. Harlin J, Csemiczky G, Wramsby H, Fried G. Recombinant follicle stimulating hormone in in-vitro fertilization treatment-clinical experience with follitropin alpha and follitropin beta. Hum Reprod. 1999;14(11):2709–2715.

51. van Wely M, Kwan I, Burt AL, et al. Recombinant versus urinary FSH in men with non-obstructive azoospermia. BMJ. 2005;331(7514):315–319.

52. Baker VL, Fujimoto YV, Kettel LM, et al. Clinical efficacy of highly purified urinary FSH versus recombinant FSH in volunteers undergoing controlled ovarian stimulation for in vitro fertilization: a randomized, multicenter, investigator-blind trial. Fertil Steril. 2009;91(4):1005–1011.

53. Sohrabvand F, Sheikhthassani S, Bagheri M, et al. Comparison of highly purified urinary versus recombinant FSH. Effect on ART outcomes in polycystic ovary syndrome. Iran J Reprod Med. 2012;10(3):229–236.
